Radiation dose effect in locally advanced non-small cell lung cancer.

Radiation is the foundation of treatment for locally advanced non-small cell lung cancer (NSCLC), and as such, optimal radiation dose is essential for successful treatment. This article will briefly review biological considerations of radiation dose and their effect in the context of three-dimensional conformal radiation therapy (3D-CRT) including intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) for NSCLC. It will focus on literature review and discussions regarding radiation dose effect in locally advanced NSCLC including potential severe and lethal toxicities of high dose radiation given with concurrent chemotherapy. Potential new approaches for delivering safe and effective doses by individualizing treatment based on functional imaging are being applied in studies such as the PET boost trial and RTOG1106. The RTOG concept of delivering high dose radiation to the more resistant tumors with the use of isotoxic dose prescription and adaptive planning will also be discussed in detail.

[1]  W. Curran,et al.  A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. , 2013 .

[2]  V. Budach,et al.  Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Hiroki Shirato,et al.  Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? , 2011, International journal of radiation oncology, biology, physics.

[4]  B. Jeremic,et al.  Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients. , 2012, International journal of radiation oncology, biology, physics.

[5]  R Mackie,et al.  A new approach to dose escalation in non-small-cell lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[6]  J. Daurès,et al.  Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Saitoh,et al.  Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study. , 2012, International journal of radiation oncology, biology, physics.

[8]  J. Herndon,et al.  Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Herndon,et al.  Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Fowler,et al.  A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. , 2010, International journal of radiation oncology, biology, physics.

[11]  N. Saijo,et al.  Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). , 2005, Japanese journal of clinical oncology.

[12]  R. T. Ten Haken,et al.  High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. , 2005, International journal of radiation oncology, biology, physics.

[13]  Jeffrey Bradley,et al.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[14]  K. Kent,et al.  Utility of radiologic review for noncardiac findings on multislice computed tomography in patients with severe aortic stenosis evaluated for transcatheter aortic valve implantation. , 2010, The American journal of cardiology.

[15]  M. Socinski,et al.  Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma , 2001, Cancer.

[16]  M. Mehta,et al.  Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jan-Jakob Sonke,et al.  Frameless stereotactic body radiotherapy for lung cancer using four-dimensional cone beam CT guidance. , 2009, International journal of radiation oncology, biology, physics.

[19]  Yongshun Chen,et al.  Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Jinming Yu,et al.  A Randomized Study of Involved-Field Irradiation Versus Elective Nodal Irradiation in Combination With Concurrent Chemotherapy for Inoperable Stage III Nonsmall Cell Lung Cancer , 2007, American journal of clinical oncology.

[21]  M. Ridder,et al.  Toxicity report of a phase 1/2 dose‐escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy , 2009, Cancer.

[22]  Tumor Cavitation in Patients With Stage III Non–Small-Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy: Incidence and Outcomes , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Yulin Song,et al.  Feasibility of implementing stereotactic body radiation therapy using a non-commercial volumetric modulated arc therapy treatment planning system for early stage lung cancer , 2011, 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[24]  M. Links,et al.  Concurrent end-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy. , 2006, Australasian radiology.

[25]  A. Bleyer,et al.  Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. , 2010, Journal of the National Cancer Institute.

[26]  S. F. C. O’Rourke,et al.  Linear quadratic and tumour control probability modelling in external beam radiotherapy , 2009, Journal of mathematical biology.

[27]  Walter J Curran,et al.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Ohmatsu,et al.  Concurrent Chemoradiotherapy with Cisplatin and Vinorelbine for Stage III Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  J. Crowley,et al.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Quynh-Thu Le,et al.  Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  J. Jett,et al.  The value of combined‐modality therapy in elderly patients with stage III nonsmall cell lung cancer , 2007, Cancer.

[32]  M. Socinski,et al.  Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium , 2004 .

[33]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[34]  R K Ten Haken,et al.  Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. , 1999, Lung cancer.

[35]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.

[36]  R. Timmerman,et al.  Stereotactic Body Radiation Therapy: A Comprehensive Review , 2007, American journal of clinical oncology.

[37]  D. Ettinger,et al.  Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. , 2002, International journal of radiation oncology, biology, physics.

[38]  K. Cease,et al.  The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer. , 2009, International journal of radiation oncology, biology, physics.

[39]  Wei Huang,et al.  Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. , 2011, International journal of radiation oncology, biology, physics.

[40]  Kurt Baier,et al.  Dose-response in stereotactic irradiation of lung tumors. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[41]  John Cho,et al.  Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. , 2012, International journal of radiation oncology, biology, physics.

[42]  R. Komaki,et al.  Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Cynthia S. Johnson,et al.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Opolon,et al.  Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. , 1996, Journal of the National Cancer Institute.

[45]  A Harvey,et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[46]  C. Koning,et al.  Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer , 2007, Radiation oncology.

[47]  Jeffrey D Bradley,et al.  Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. , 2002, International journal of radiation oncology, biology, physics.

[48]  Yue Cao,et al.  Metabolic tumor volume on PET reduced more than gross tumor volume on CT during radiotherapy in patients with non-small cell lung cancer treated with 3DCRT or SBRT , 2013, Journal of Radiation Oncology.

[49]  R. Arriagada,et al.  Current strategies for radiation therapy in non-small cell lung cancer. , 1997, Chest.

[50]  Nianwen Xue,et al.  Temporal relation discovery between events and temporal expressions identified in clinical narrative , 2013, J. Biomed. Informatics.

[51]  M. Socinski,et al.  Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. , 2011, International journal of radiation oncology, biology, physics.

[52]  Jeffrey D Bradley,et al.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.

[53]  P. van Houtte,et al.  A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. , 2009, Lung cancer.

[54]  C. Ling,et al.  Results of a phase I dose‐escalation study using three‐dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma , 2005, Cancer.

[55]  G. Jiang,et al.  A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[56]  E. Borden,et al.  Recombinant Human Interferon-β (rHuIFN-β) and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer , 1996 .

[57]  Benjamin Movsas,et al.  Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. , 2012, International journal of radiation oncology, biology, physics.

[58]  E. Cortesi,et al.  Clinical outcomes of single dose stereotactic radiotherapy for lung metastases. , 2013, Clinical lung cancer.

[59]  Randall K Ten Haken,et al.  Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.

[60]  C. Ling,et al.  Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[61]  V. De Sanctis,et al.  Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer. , 2013, International journal of radiation oncology, biology, physics.

[62]  J. Herndon,et al.  Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.

[63]  Indrin J Chetty,et al.  A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Matthias Guckenberger,et al.  Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[65]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[66]  H Jaradat,et al.  Dose Escalated, Hypofractionated Radiotherapy Using Helical Tomotherapy for Inoperable Non-Small Cell Lung Cancer: Preliminary Results of a Risk-Stratified Phase I Dose Escalation Study , 2008, Technology in cancer research & treatment.

[67]  Pranshu Mohindra,et al.  Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Socinski,et al.  Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Matthias Guckenberger,et al.  Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.

[70]  L. Boersma,et al.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.